Trials / Terminated
TerminatedNCT02771626
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Calithera Biosciences, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CB-839 | Glutaminase inhibitor |
| DRUG | Nivolumab | PD-1 inhibitor |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2020-04-24
- Completion
- 2020-04-24
- First posted
- 2016-05-13
- Last updated
- 2023-03-17
- Results posted
- 2023-03-17
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02771626. Inclusion in this directory is not an endorsement.